Trial Information

Summary: Study of Tamoxifen and Raloxifene for the Prevention of Breast Cancer (STAR)

The Queens Cancer Center of Queens Hospital Center in conjunction with the National Cancer Institute (NCI) and the NSABP (National Surgical Adjuvant Breast and Bowel Project) is currently conducting STAR. Recently, clinical research studies have shown that Tamoxifen will actually prevent breast cancer in many women. Raloxifene, a medication similar to Tamoxifen has been studied for many years and has been approved for osteoporosis prevention, but it is investigational for use in breast cancer prevention. It's effectiveness in preventing breast cancer will be compared to Tamoxifen in the STAR clinical research study.

You will not be compensated for your time, however, research study medication will be provided at no cost to you.

You may be eligible to participate in the above study if you:

• Are postmenopausal (have not had your period for 12 consecutive months)
• Have not been on hormones for at least 3 months
• Are determined to be at risk for breast cancer based on family and medical histories (determined by STAR risk assessment form)

• Have been diagnosed with breast cancer
• Have a history of blood clots, uncontrolled high blood pressure or diabetes
• Are taking anticoagulants such as Coumadin

If you would like to learn more about participating in this study, please send an e-mail message using the form below.